JoelPicusMD

Oncology • Saint Louis, MO

Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology

Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine

Join to view full profile

Dr. Picus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Picus' full profile

Already have an account?

Office
4921 Parkview Pl
7th Floor
Saint Louis, MO 63110
Phone+1 314-747-1171

Fax+1 314-362-3192
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1987 - 1990
Duke University HospitalResidency, Internal Medicine, 1984 - 1987
Harvard Medical SchoolClass of 1984

Certifications & Licensure

MO State Medical License 1991 - 2025
NC State Medical License 1986 - 2024
CA State Medical License 1987 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Hormone Therapy in Treating Patients With Prostate Cancer Start of enrollment: 1998 May 01
Completed
Phase 2
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2001 Jun 01
Completed
Phase 2
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Start of enrollment: 2005 Aug 12
Terminated
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies Start of enrollment: 2008 Mar 01
Completed
Phase 1
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies Start of enrollment: 2008 Mar 08
Completed
Phase 1
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
Completed
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Jun 01
Unknown status
Phase 1, Phase 2
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2012 Apr 01
Completed
Phase 1
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Start of enrollment: 2009 Dec 16
Completed
Phase 1
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Start of enrollment: 2013 May 14
Completed
Phase 4
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer Start of enrollment: 2013 Nov 08
Completed
Phase 2
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (A...
Rahul Aggarwal, Glenn Heller, David W Hillman, Han Xiao, Joel Picus, Mary-Ellen Taplin, Tanya Dorff, Leonard Appleman, Douglas Weckstein, Akash Patnaik, Alan Bryce, Da...> ;Journal of Clinical Oncology. 2024 Apr 1
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
Petrylak, D., Eigl, B., George, S., Heath, E., Hotte, S., Chism, D., Nabell, L., Picus, J., Cheng, S., Appleman, L., Sonpavde, G., Morgans, A., Pourhosseini, P., Wu, R...> ;Clinical Cancer Research. 2024 Jan 5
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel, P., Sweis, R., Bupathi, M., Heath, E., Goodman, O., Hoimes, C., Milowsky, M., Davis, N., Kalebasty, A., Picus, J., Shaffer, D., Mao, S., Adra, N., Yorio, J., ...> ;European Urology Oncology. 2023 Dec 16
49 citations
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, William H Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M Salay, Tracee L McMiller, M...> ;Journal of Clinical Oncology. 2023 Feb 1
2 citations
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Alicia K Morgans, Yu-Hui Chen, David F Jarrard, Michael Carducci, Glenn Liu, Mario Eisenberger, Elizabeth R Plimack, Alan Bryce, Jorge A Garcia, Robert Dreicer, Nichol...> ;The Prostate. 2022 Sep 1
4 citations
Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemoth...
Benjamin W Fischer-Valuck, Sagar A Patel, Randall J Brenneman, John Christodouleas, Paul Sargos, Eric Kim, Aaron Weiss, Bruce Hershatter, Yuan J Rao, Joel Picus, Bruce...> ;European Urology Oncology. 2022 Apr 1
4 citations
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial
Susan Halabi, Qian Yang, Andrea Carmack, Shiqi Zhang, Wen-Chi Foo, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Rober...> ;Kidney Cancer Journal. 2021 Sep 30
4 citations
Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
Manik Amin, Feng Gao, Gretel Terrero, Joel Picus, Andrea Wang-Gillam, Rama Suresh, Cynthia Ma, Benjamin R. Tan, Maria Q. Baggstrom, Michael J. Naughton, Lauren Trull, ...> ;American Journal of Clinical Oncology. 2021 Sep 1
5 citations
Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.
Kian-Huat Lim, Mateusz Opyrchal, Abhi Acharya, Nick Boice, Ningying Wu, Feng Gao, Jace Webster, Albert C. Lockhart, Saiama N. Waqar, Ramaswamy Govindan, Daniel Morgens...> ;European Journal of Cancer. 2021 Jul 10
3 citations
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert ...> ;Clinical Cancer Research. 2021 Jun 15
25 citations
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Jonathan E. Rosenberg, Karla A Ballman, Susan Halabi, Pamela J. Atherton, Amir Mortazavi, Christopher Sweeney, Walter M. Stadler, Benjamin A. Teply, Joel Picus, Scott ...> ;Journal of Clinical Oncology. 2021 May 14
14 citations
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Katrina S. Pedersen, Patrick M. Grierson, Joel Picus, A. Craig Lockhart, Bruce J. Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang, Andrea Wang...> ;Investigational New Drugs. 2021 Mar 18
10 citations
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert ...> ;Clinical Cancer Research. 2021 Jun 15
6 citations
Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemorad...
Benjamin W. Fischer-Valuck, Jeff M. Michalski, Joanna Harton, Alison Birtle, John P. Christodouleas, Jason A. Efstathiou, Vivek K. Arora, Eric H. Kim, Eric M. Knoche, ...> ;Clinical Genitourinary Cancer. 2021 Feb 1
14 citations
Cell-Free DNA Alterations in the AR Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer
Ha X. Dang, Pradeep S. Chauhan, Haley Ellis, Wenjia Feng, Peter K. Harris, Grace Smith, Mark Qiao, Katherine Dienstbach, Rachel Beck, Andrew Atkocius, Faridi Qaium, Ji...> ;JCO Precision Oncology. 2020 Jun 18
1 citations
Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate.
Hal A. Lewis, David Y. Chen, Ilana S. Rosman, Joel Picus, Milan J. Anadkat> ;Dermatology Online Journal. 2020 Jun 15
83 citations
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Matthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky, Saby George, Sumati Gupta, Mark D. Fleming, Long H. Dang, Daniel M. Geynisman, Radhika Walling, Robert S. Alter...> ;Journal of Clinical Oncology. 2020 Apr 9
271 citations
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Timothy D Gilligan, Daniel W. Lin, Rahul Aggarwal, David D. Chism, Nicholas G. Cost, Ithaar Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L...> ;Journal of the National Comprehensive Cancer Network. 2019 Dec 1
17 citations
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN...
Daniel J. George, Colin Hessel, Susan Halabi, M. Dror Michaelson, Olwen Hahn, Meghara K. Walsh, Joel Picus, Eric J. Small, Shaker R. Dakhil, Darren R. Feldman, Milan M...> ;The Oncologist. 2019 Aug 9
16 citations
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
Susan F. Slovin, Syed A. Hussain, Fred Saad, Jorge A. Garcia, Joel Picus, Roberta Ferraldeschi, Mateus Crespo, Penelope Flohr, Ruth Riisnaes, Chihche Lin, Harold N. Ke...> ;Clinical Cancer Research. 2019 Aug 1
6 citations
Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer
Manik Amin, Monica Dandona Desai, Kathryn Trinkaus, Amberly Brown, Andrea Wang-Gillam, Benjamin R. Tan, Joel Picus, Steven Sorscher, Maureen Highkin, Kim Lears, Albert...> ;Journal of Gastrointestinal Oncology. 2019 Apr 3
32 citations
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Petros Grivas, Amir Mortazavi, Joel Picus, Noah M. Hahn, Matthew I. Milowsky, Lowell L. Hart, Ajjai Alva, Joaquim Bellmunt, Sumanta K. Pal, Richard Martin Bambury, Pet...> ;Cancer. 2019 Feb 15
17 citations
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using ...
Benjamin W. Fischer-Valuck, Jeff M. Michalski, Jessika Contreras, Randall Brenneman, John P. Christodouleas, Christopher Abraham, Eric H. Kim, Vivek K. Arora, Arnold B...> ;Clinical and Translational Radiation Oncology. 2019 Feb 1
5 citations
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised ...
Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson, Olwen Hahn, Meghara K. Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Da...> ;European Journal of Cancer. 2018 Sep 27
26 citations
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
Jonathan E. Rosenberg, Noah M. Hahn, Meredith M. Regan, Lillian Werner, Ajjai Alva, Saby George, Joel Picus, Robert S. Alter, Arjun Vasant Balar, Jean H. Hoffman-Censi...> ;British Journal of Cancer. 2018 May 1
Join now to see all